C4XD says to start clinical trials for its drug candidate to treat addiction

23 September 2015

C4X Discovery Holdings (LSE: C4XD) on Wednesday said its drug compound Orexin-1 to treat addiction is in formal pre-clinical safety and toxicity studies ahead of the start of clinical trials.

The company said it expects to file a clinical trial application to enable human studies at the end of 2016.

Chief executive Piers Morgan, said: “We continue to make outstanding progress with our proprietary programs, which are focused on areas of high unmet medical need, with large target markets. Our technology enables us to design novel, selective, potent leads and drug candidates in a fraction of the time and cost compared to conventional methods.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK